Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 8:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 379 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Acneiform Rash Clear all
Completed Not applicable Interventional Accepts healthy volunteers

RCT of an Oral Acne Supplement for Adult Women

NCT06097871
View directory record Official record
Conditions
Acne
Interventions
Skin Nutraceutical Supplement, Placebo pill
Dietary Supplement · Other
Lead sponsor
Nutraceutical Wellness Inc.
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Sep 5, 2026, 8:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Fractional Radiofrequency for Treatment of Acne Scars and Wrinkles

NCT05827510
View directory record Official record
Conditions
Acne, Wrinkle
Interventions
BTL-585F
Device
Lead sponsor
BTL Industries Ltd.
Industry
Eligibility
21 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Davie, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 1, 2024 · Synced Sep 5, 2026, 8:15 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Weekly Isotretinoin Therapy Study

NCT04594759
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Isotretinoin
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
12 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 8, 2022 · Synced Sep 5, 2026, 8:15 AM EDT
Completed Not applicable Interventional

The Development and Evaluation of an "E-Visit" Program for the Management of Acne

NCT00417456
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Evisit, Office visit
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
12 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 15, 2012 · Synced Sep 5, 2026, 8:15 AM EDT
Completed Phase 3 Interventional

Trial of Dapsone 5.0% Gel in the Treatment of Acne Vulgaris

NCT02865005
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Dapsone 5.0% Gel (SEEGPharm), Placebo, Dapsone 5.0% Gel (Allergan)
Drug · Other
Lead sponsor
Seegpharm S.A.
Industry
Eligibility
12 Years to 40 Years
Enrollment
2,361 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
35
States / cities
Encino, California • Fullerton, California • La Mesa, California + 29 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2016 · Synced Sep 5, 2026, 8:15 AM EDT
Completed Phase 1 Interventional

Absorption and Systematic Pharmacokinetics of IDP-123 Lotion in Comparison With Tazorac Cream

NCT02849873
View directory record Official record
Conditions
Acne
Interventions
IDP-123 Lotion, Tazorac Cream
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
9 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Sep 5, 2026, 8:15 AM EDT
Completed Phase 4 Interventional Results available

Treatment of Acne Vulgaris With Doryx Tablets Compared to Doxycyline Hyclate

NCT00635609
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Doxycycline hyclate (Doryx), Doxycycline hyclate
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
12 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
4
States / cities
Vista, California • Miami, Florida • Louisville, Kentucky + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2012 · Synced Sep 5, 2026, 8:15 AM EDT
Completed Phase 4 Interventional Results available

A Study to Compare Efficacy and Safety of Trifarotene Cream When Used With an Oral Antibiotic for the Treatment of Severe Acne Vulgaris (AV)

NCT04451330
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Trifarotene cream, Doxycycline hyclate, Trifarotene Vehicle, Doxycycline Placebo
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
25
States / cities
Fort Smith, Arkansas • Hot Springs, Arkansas • Rogers, Arkansas + 21 more
Source: ClinicalTrials.gov public record
Updated May 9, 2022 · Synced Sep 5, 2026, 8:15 AM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Impact of Clascoterone 1% Cream on Skin Barrier Properties in Acne Prone Patients

NCT06415292
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Winlevi (clascoterone) 1% cream
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Sep 5, 2026, 8:15 AM EDT
Completed Not applicable Interventional

Teledermatology and Modulation of Antibiotic Dose in Acne Vulgaris

NCT02905851
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Feedback group, Non Feedback group
Other
Lead sponsor
University of California, Davis
Other
Eligibility
15 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 1, 2018 · Synced Sep 5, 2026, 8:15 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Evaluate Safety and Efficacy of an OC Preparation vs Placebo for 6 Treatment Cycles in Women With Moderate Acne.

NCT00651469
View directory record Official record
Conditions
Acne Vulgaris
Interventions
YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
14 Years to 45 Years · Female only
Enrollment
534 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2004
U.S. locations
27
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2014 · Synced Sep 5, 2026, 8:15 AM EDT
Withdrawn Phase 2Phase 3 Interventional Accepts healthy volunteers

Topical 5% Tranexamic Acid as a Treatment for Postinflammatory Hyperpigmentation Due to Acne Vulgaris

NCT03361345
View directory record Official record
Conditions
Postinflammatory Hyperpigmentation
Interventions
Tranexamic Acid, Vehicle
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Dearborn, Michigan
Source: ClinicalTrials.gov public record
Updated May 15, 2023 · Synced Sep 5, 2026, 8:15 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Clinical Trial in Subjects With Mild to Moderate Acne Vulgaris

NCT02832063
View directory record Official record
Conditions
Acne Vulgaris
Interventions
B244, Placebo
Biological
Lead sponsor
AOBiome LLC
Industry
Eligibility
18 Years and older
Enrollment
372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Culver City, California
Source: ClinicalTrials.gov public record
Updated Sep 15, 2022 · Synced Sep 5, 2026, 8:15 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study Comparing the Safety and Efficacy of IDP-120 Gel and IDP-120 Vehicle Gel in the Treatment of Acne Vulgaris

NCT03664739
View directory record Official record
Conditions
Acne Vulgaris
Interventions
IDP-120 Gel, IDp-120 Vehicle Gel
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
9 Years and older
Enrollment
608 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
25
States / cities
Mobile, Alabama • Hot Springs, Arkansas • Beverly Hills, California + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2023 · Synced Sep 5, 2026, 8:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Open-label Safety and Tolerability Study of LTS-PDT in Healthy Volunteers

NCT01830764
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Red Light (PDT)
Drug
Lead sponsor
Dermira, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Paramus, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 19, 2021 · Synced Sep 5, 2026, 8:15 AM EDT
Completed Not applicable Interventional

Safety & Effectiveness of the BEAM Device in Mild-to-moderate Acne

NCT01162837
View directory record Official record
Conditions
Acne
Interventions
BEAM device
Device
Lead sponsor
Oregon Aesthetic Technologies
Industry
Eligibility
15 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
3
States / cities
Miami Beach, Florida • Warren, Michigan • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 2, 2012 · Synced Sep 5, 2026, 8:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Potential of Tazarotene Foam to Cause a Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers

NCT01115322
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Tazarotene Foam without irradiation, Tazarotene Foam with UVA and UVB irradiation, Tazarotene Foam with UVA, UVB, and visible light, Vehicle Foam without irradiation, Vehicle Foam with UVA and UVB irradiation, Vehicle Foam with UVA and UVB and visible light irradiation, No Treatment without irradiation, No Treatment with UVA and UVB irradiation, No Treatment with UVA and UVB and visible light irradiation
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 19, 2017 · Synced Sep 5, 2026, 8:15 AM EDT
Completed Phase 3 Interventional Results available

Adapalene-Benzoy Peroxide (BPO) Gel in the Treatment of Acne Vulgaris as a 6-month Maintenance

NCT00687908
View directory record Official record
Conditions
Acne
Interventions
Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel, Vehicle Gel
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years to 35 Years
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
27
States / cities
San Diego, California • Denver, Colorado • Longmont, Colorado + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Sep 5, 2026, 8:15 AM EDT
Completed Phase 3 Interventional Results available

A Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel in Subjects With Acne Vulgaris

NCT00421993
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Adapalene/Benzoyl Peroxide, Adapalene, Benzoyl Peroxide, Topical Gel Vehicle
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years and older
Enrollment
1,670 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
33
States / cities
Huntsville, Alabama • Little Rock, Arkansas • Fresno, California + 30 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Sep 5, 2026, 8:15 AM EDT
Completed Phase 2 Interventional Results available

Double-Blind, Placebo-Controlled Study to Evaluate 3 Doses of a Novel Tetracycline in the Treatment of Facial Acne Vulgaris

NCT01628549
View directory record Official record
Conditions
Acne Vulgaris
Interventions
50 mg P005672-HCl, Placebo, 100 mg P005672-HCl
Drug
Lead sponsor
Almirall, S.A.
Industry
Eligibility
12 Years to 45 Years
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
38
States / cities
Mobile, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2019 · Synced Sep 5, 2026, 8:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, 3 Day Study of Safety and Tolerability of NVN1000 Topical Gel in Healthy Volunteers

NCT01755247
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Topical Gel Vehicle, 8% NVN1000 Topical Gel, 8% NVN1000 Topical Gel and moisturizer
Drug
Lead sponsor
Novan, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Broomall, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Sep 5, 2026, 8:15 AM EDT
Completed Phase 3 Interventional

DMT310-009 Topical in the Treatment of Acne Vulgaris

NCT06090721
View directory record Official record
Conditions
Acne Vulgaris
Interventions
DMT310, Placebo
Drug
Lead sponsor
Dermata Therapeutics
Industry
Eligibility
9 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Freemont, California • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced Sep 5, 2026, 8:15 AM EDT
Completed Phase 4 Interventional Results available

A Study of Different Use Regimens Using Two Acne Treatments

NCT00907257
View directory record Official record
Conditions
Acne Vulgaris
Interventions
benzoyl peroxide wash, Tretinoin gel
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
12 Years and older
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
12
States / cities
Boca Raton, Florida • Miami, Florida • Snellville, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2012 · Synced Sep 5, 2026, 8:15 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne

NCT06316297
View directory record Official record
Conditions
Acne
Interventions
Acne mRNA vaccine, Placebo
Biological · Other
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 45 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
79
States / cities
Scottsdale, Arizona • Cerritos, California • Encino, California + 64 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 5, 2026, 8:15 AM EDT